Received Feb 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
skin rashes/eruption of skin; nausea; headache; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of rash in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Additional patient notes included patient past medical history and concurrent condition were not reported. On an unknown date, the patient received Shingrix. On 07-DEC-2021, an unknown time after receiving Shingrix, the patient experienced rash (Verbatim: skin rashes/eruption of skin), nausea (Verbatim: nausea) and headache (Verbatim: headache). The outcome of the rash, nausea and headache were not reported. It was unknown if the reporter considered the rash, nausea and headache to be related to Shingrix. It was unknown if the company considered the rash, nausea and headache to be related to Shingrix. Additional Information: GSK Receipt Date: 13-FEB-2026 The batch number was not provided and unable to contact the reporter.
Comments: patient past medical history and concurrent condition were not reported